Relapsed and refractory hodgkin lymphoma

Hodgkin Lymphoma: A Comprehensive Overview, Second Edition

Volumn , Issue , 2015, Pages 321-330

  von Tresckow, Bastian ^a   Moskowitz, Craig ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Brentuximab vedotin; Hodgkin lymphoma; PET; Refractory; Relapse; Transplantation

Indexed keywords

EID: 84955734174     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-12505-3_19     Document Type: Chapter

References (44)

1. Linch DC, Winfi eld D, Goldstone AH, Moir D, Hancock B, Mc Millan A et al (1993) Dose intensifi cation with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341(8852):1051-1054
2. Schmitz N, Pfi stner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet 359(9323):2065-2071. doi: 10.1016/S0140-6736(02)08938-9
3. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 124(5):645-652
4. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J et al (2004) Treatment for primary refractory Hodgkin’s disease: A comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 33(12):1225-1229. doi: 10.1038/sj.bmt.1704508
5. Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A et al (2003) Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome. Ann Oncol 14(5):745-751
6. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC (1979) Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after fi rst relapse. Ann Intern Med 90(5):761-763
7. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 20(1):221-230
8. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97(3):616-623
9. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphsoma autografted after a fi rst relapse. Ann Oncol 16(4):625-633. doi: 10.1093/annonc/mdi119
10. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O et al (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 20(2):467-475
11. Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H et al (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 28(34):5074-5080. doi: 10.1200/JCO.2010.30.5771
12. Brice P, Bouabdallah R, Moreau P, Divine M, Andre M, Aoudjane M et al (1997) Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: Analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 20(1):21-26. doi: 10.1038/sj.bmt.1700838
13. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14(1):123-130
14. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23):4934-4937. doi: 10.1182/blood-2010-05-282756
15. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A et al (2012) Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy. Haematologica. doi: 10.3324/haematol.2011.056051
16. Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V et al (2013) Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 98(8):1185-1195. doi: 10.3324/haematol.2012.072090
17. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J et al (2010) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the signifi cance of pre- transplant functional imaging. Br J Haematol 148(6):890-897. doi: 10.1111/j.1365-2141.2009.08037.x
18. Moskowitz C (2004) An update on the management of relapsed and primary refractory Hodgkin’s disease. Semin Oncol 31(2 Suppl 4):54-59
19. Fernandez-Jimenez Mc, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernandez-Navarro F (1999) Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin’s disease prior to autologous peripheral blood stem cell transplantation. Haematologica 84(11):1007-1011
20. Martin A, Fernandez-Jimenez Mc, Caballero MD, Canales MA, Perez-Simon JA, de Bustos JG et al (2001) Long-term follow-up in patients treated with Mini- BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 113(1):161-171
21. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al (1998) Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4(2):311-316
22. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A (1990) Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant 5(2):99-103
23. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH et al (2002) Time-intensifi ed dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 13(10):1628-1635
24. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K et al (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 18(6):1071-1079. doi: 10.1093/annonc/mdm090
25. Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M et al (2007) IGEV regimen and a fi xed dose of lenograstim: An effective mobilization regimen in pretreated Hodgkin’s lymphoma patients. Bone Marrow Transplant 40(11):1019-1025. doi: 10.1038/sj.bmt.1705862
26. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin Lymphoma. Cancer 106(2):353-360. doi: 10.1002/cncr.21587
27. Moskowitz AJ (2013) PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma. International Symposium on Hodgkin Lymphoma: Germany
28. Yasuhiro O, Fanale M, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A (2013) A phase I study Of panobinostat in combination with iCE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL). Blood 122(21):252
29. A. H (2012) Phase I/II feasibility study combining Brentuximab Vedotin (SGN-35; Adcetris) with second line salvage chemotherapy (DHAP) in Hodgkin Lymphoma patients refractory to fi rst line chemotherapy or in fi rst relapse who are eligible for high dose treatment followed by autologous peripheral blood stem cell transplantation. American Society of Hematology Annual Meeting
30. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM et al (2012) Hodgkin Lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Nat Compr Cancer Netw 10(5):589-597
31. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A (2014) Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 Octobe Leuk Lymphoma 55(1):31-37. doi: 10.3109/10428194.2013.802784
32. Mocikova H, Pytlik R, Markova J, Steinerova K, Kral Z, Belada D et al (2011) Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 52(9):1668-1674. doi: 10.3109/10428194.2011.573889
33. Sweetenham JW (2011) “Pet negativity”-the new goal of cytoreductive therapy in Hodgkin’s Lymphoma? Biol Blood Marrow transplant: J Am Soc Blood Marrow Transplant 17(11):1569-1570. doi: 10.1016/j.bbmt.2011.08.006
34. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin Lymphoma. Blood 119(7):1665-1670. doi: 10.1182/blood-2011-10-388058
35. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J (2008) Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol 26(32):5240-5247. doi: 10.1200/JCO.2007.15.5507
36. Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D et al (2007) Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Ann Oncol 18(4):679-688. doi: 10.1093/annonc/mdl496
37. Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood. doi: 10.1182/blood-2010-09-288373
38. Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R et al (2008) Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for fi rst relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26(36):5980-5987. doi: 10.1200/JCO.2007.15.5887
39. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118(12):3419-3425. doi: 10.1182/blood-2011-04-351924
40. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R et al (2010) Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 16(8):1145-1154. doi: 10.1016/j.bbmt.2010.02.022
41. Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M et al (2005) Cologne highdose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16(1):116-123. doi: 10.1093/annonc/mdi003
42. Sibon D, Resche-Rigon M, Morschhauser F, Fermé C, Dupuis J, Marçais A et al (2013) Outcome of patients treated with autologous stem-cell transplantation for fi rst relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA/SFGM-TC H96 trial. Haematologica 98(supplement 2):1-64
43. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T et al (2007) Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin Lymphoma. Biol Blood Marrow Transplant 13(5):594-600. doi: 10.1016/j.bbmt.2007.01.072
44. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97(2):310-317